Article

An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalised Immunotherapy and FGFR2 Inhibiter

2023-12-04

Abstract excerpt

Advanced intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy which shows poor response to first-line treatments including radiotherapy, chemotherapy and targeted therapy. Its prognosis is extremely poor, with an overall survival of less than one year. Individualised neoantigen vaccines have shown to be effective in boosting the immune response against tumours, and neoantigen-based peptide as we...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6df65c0a-a08d-5ff2-9045-82bcf6e02a30
DOI: 10.21203/rs.3.rs-3687413/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalised Immunotherapy and FGFR2 InhibiterDOI 10.21203/rs.3.rs-3687413/v1Read

Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.Semantic proximity Read

The Immune–Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel ImmunotherapiesSemantic proximity Read

Neoantigens heterogeneity as a prognostic marker in patients with resected intrahepatic cholangiocarcinomaSemantic proximity Read

Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis.Semantic proximity Read

Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.Semantic proximity Read

Neoantigen polypeptide vaccines induce effective antitumor response in colorectal cancerSemantic proximity Read

Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future DirectionsSemantic proximity Read

Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma.Semantic proximity Read

Personalized mRNA Vaccine Combined with PD-1 Inhibitor Therapy in a Patient with Advanced Esophageal Squamous Cell CarcinomaSemantic proximity Read

A Peptide-Based Neoantigen Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard TreatmentSemantic proximity Read

Individualised neoantigen cancer vaccine therapy.Semantic proximity Read

Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cellsSemantic proximity Read